<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305095</url>
  </required_header>
  <id_info>
    <org_study_id>3648634</org_study_id>
    <secondary_id>MD009118-01</secondary_id>
    <nct_id>NCT02305095</nct_id>
  </id_info>
  <brief_title>Genomic Response Analysis of Heart Failure Therapy in African Americans</brief_title>
  <acronym>GRAHF-2</acronym>
  <official_title>Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine
      (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction
      (HFrEF) when compared to similar white cohorts. This study will seek to confirm the previous
      genetic sub-study from AHeFT which suggested a functional polymorphism of guanine nucleotide
      binding protein beta polypeptide 3 subunit (GNB3), C825T in exon 10, influences the
      therapeutic efficacy of FDC I/H. This study will initiate treatment with FDC I/H in 500 self
      designated African American subjects with systolic heart failure. They will be followed for
      up to two years on therapy. Clinical outcomes (survival, heart failure hospitalizations, and
      change in quality of life) on FDC I/H will be compared by GNB3 genotype subset. The
      hypothesis to be confirmed is that subjects homozygous for the T allele (those with the GNB3
      TT genotype which is present in approximately 50% of black subjects) demonstrate enhanced
      therapeutic benefit from FDC I/H.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine
      (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction
      (HFrEF) when compared to similar white cohorts. Despite the clear survival benefits of
      treatment with FDC I/H in the African American Heart Failure Trial (AHeFT), the drug is
      prescribed in only 25% of black subjects who would potentially benefit.

      In terms of the enhanced response evident in the A-HeFT investigation, race is likely a
      marker of differences in genomic background. Genetic variation of the G protein beta sub unit
      GNB3 has been studied extensively for its role in hypertension. A polymorphism exists at
      position 825 (T/C) which is functionally silent but tightly linked to a splicing variant
      resulting in a truncated protein. The GNB3 T haplotype is far more prevalent in blacks and
      associated with low renin hypertension. Evaluation of 350 subjects in the genetic sub-study
      of AHeFT suggests that the GNB3 TT genotype, found in 50% of African Americans but only
      10-15% of whites, was linked to an enhanced therapeutic response to FDC I/H. This
      investigation will evaluate the hypothesis that the GNB3 TT genotype is a marker of enhanced
      therapeutic response to FDC I/H in African Americans with HFrEF.

      The study will enroll a cohort of 500 African Americans with HFrEF, initiate therapy with FDC
      I/H and follow them for up to two years. Subjects will be genotyped at entry for the GNB3
      polymorphism and response to therapy compared by genotype. Therapeutic response will be
      quantified using the composite score, the primary endpoint of AHeFT, which incorporates
      mortality, heart failure hospitalizations, and a change in quality of life (QoL) score at six
      months.

      Aim 2 will do a similar analysis of response to therapy by GNB3 genotype using improvement in
      left ventricular end diastolic diameter (LVEDD) or left ventricular ejection fraction (LVEF)
      by echocardiogram after six months on therapy as the outcomes measure. Aim 3 will use
      admixture analysis to determine first how global ancestry (the % African ancestral DNA for an
      individual) impacts on the outcome measures of drug response, and how the global ancestry
      acts as a modifier for the effect of GNB3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite score (CS) no units. (survival, heart failure hospitalization, and change in the raw quality of life score on the Minnesota Living with Heart Failure Questionnaire)</measure>
    <time_frame>2 years</time_frame>
    <description>The CS combines three outcome variables into a single &quot;score&quot;. Composite score adds points for survival over 2 years of follow up (death at any time yields -3 points, survival to end of study results in 0), heart failure hospitalization over 2 years of follow up (yes at any time results in -1 point, no results in 0), and the change in the raw quality of life score on the Minnesota Living with Heart Failure Questionnaire from entry to 6 months (change of ten units or greater=increase +2, decrease-2; change 5 to 9= increase+1, decrease -1; change &lt; 5 units for the raw score yields 0 points). The CS will range from -6 to +2 for each patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of survival on therapy by GNB3 genotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free from heart failure hospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of event free survival by GNB3 genotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessment by Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the change in the raw score of the Quality of Life questionnaire by GNB3 genotype.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>GNB3 TT</arm_group_label>
    <description>All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNB3 C</arm_group_label>
    <description>All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC I/H</intervention_name>
    <description>All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines</description>
    <arm_group_label>GNB3 TT</arm_group_label>
    <arm_group_label>GNB3 C</arm_group_label>
    <other_name>BiDil</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and DNA banked at baseline.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects with systolic heart failure who are self designation as African Americans
        are potentially eligible for the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years and older

          2. History of heart failure with an LVEF (less than OR equal to) &lt; 0.35 for at least 6
             months OR an LVEF &lt; 0.45 with left ventricular internal end diastole (defined by a
             diameter of more than 2.9 cm per square meter of body surface area OR more than 6.5 cm
             on the basis of echocardiography). ** Echo must be done within 6 months of
             enrollment**

          3. New York Heart Association (NYHA) Class II-IV

          4. Background heart failure therapy that includes angiotensin converting enzyme
             inhibitors (ACEi) or angiotensin receptor blockers (ARBs), and beta blockers (BBs) for
             at least 3 months (or documentation of intolerance to ACEi/ARBs and BBs)

          5. Self-designated race as African American or black (would include subjects whose
             country of origin was outside the USA such as Africa, the Caribbean, or Central
             America).

        Exclusion Criteria:

          1. History of intolerance to either nitrates or hydralazine

          2. Treatment with the combination of hydralazine and nitrates for the previous 3 months

          3. Revascularization or myocardial infarction within last 90 days

          4. Received cardiac resynchronization therapy (CRT) AND did not have an assessment of
             cardiac function documenting an LVEF &lt; 35% (less than OR equal to 35%) at least 90
             days post CRT

          5. Presence of clinically significant valvular heart disease, hypertrophic or restrictive
             cardiomyopathy, active myocarditis, or uncontrolled hypertension. (Note that
             uncontrolled hypertension is defined as blood pressure consistenly greater than 160
             mmHg systolic and 95 mmHg diastolic)

          6. Women who are currently pregnant, planning on becoming pregnant in the next two years,
             or those who do not agree to prevent pregnancy.

          7. Subjects who are on continuous home inotropes, a left ventricular assist device, or
             who are post cardiac transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis McNamara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Medical Center</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy Alexander</last_name>
      <phone>205-934-8767</phone>
      <email>bla35950@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Sumanth D Prabhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Olmos</last_name>
      <phone>904-953-2255</phone>
      <email>olmos.judy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Ung, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Ann Cross</last_name>
      <phone>404-616-8851</phone>
      <email>jcross@msm.edu</email>
    </contact>
    <investigator>
      <last_name>Adeisayo Oduwole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erikka Woolfolk</last_name>
      <phone>404-712-1961</phone>
      <email>ewoolf2@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natasha Mann</last_name>
      <email>natasha.mann@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alanna Morris, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Crooke, RN</last_name>
      <phone>312-695-4189</phone>
      <email>ccrooke@nm.org</email>
    </contact>
    <investigator>
      <last_name>Allen Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Leigh</last_name>
      <phone>312-413-2948</phone>
      <email>leighj@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Gans, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Heart and Vascular Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Bowers</last_name>
      <phone>504-988-2030</phone>
      <email>sbowers@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Abhishek Jaiswal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Boudet</last_name>
      <phone>504-842-5257</phone>
      <email>kboudet@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Ken Bode</last_name>
      <email>ken.bode@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hector Ventura, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Marshall, RN, MS</last_name>
      <phone>410-328-7623</phone>
      <email>jmarshal1@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Gautam V Ramani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachsetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rina Romano</last_name>
      <phone>617-643-6328</phone>
      <email>rbromano@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Newton-Cheh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Leszcynski, RN, CCRC</last_name>
      <phone>313-916-3502</phone>
      <email>kleszcz2@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Ahlam Almawri</last_name>
      <email>aalmawr1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Lanfear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University Health Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khyati Mehta</last_name>
      <email>mehtaka@sph.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Pallavi Solanki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Bronx New York</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Maaz</last_name>
      <phone>718-904-3293</phone>
      <email>miqbal@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>James M Tauras, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Nichols, RN</last_name>
      <phone>216-778-2223</phone>
      <email>jnichols@metrohealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennie Wong, RN, CCRP</last_name>
      <phone>215-707-8191</phone>
      <email>jennie.wong@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Dries, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci McGaha</last_name>
      <phone>412-692-4828</phone>
      <email>mcgahatl4@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis McNamara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Everidge</last_name>
      <phone>843-792-2944</phone>
      <email>adamsde@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vijay Paladugu</last_name>
      <email>paladugc@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian Van Bakel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular Foundation</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Fondren</last_name>
      <phone>901-271-4064</phone>
      <email>kfond@sterncardio.com</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Austin</last_name>
      <email>naust@sterncardio.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frank McGrew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Ramer Young</last_name>
      <phone>713-794-8757</phone>
      <email>Angela.Young@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denita Robertson</last_name>
      <email>denita.robertson@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Biykem Bozkuert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Brunk</last_name>
      <phone>434-982-1058</phone>
      <email>SLB4P@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Bailes</last_name>
      <email>LGS2M@hscmail.mcc.virignia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Buda, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Dennis McNamara</investigator_full_name>
    <investigator_title>Professor of Medicine and Director, Center for Heart Failure Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

